Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Ottawa Score Performs Poorly to Identify Cancer Patients at High Risk of Recurrent Venous Thromboembolism: Insights from the TROPIQUE Study and Updated Meta-Analysis.
Frere C, Crichi B, Wahl C, Lesteven E, Connault J, Durant C, Rueda-Camino JA, Yannoutos A, Bensaoula O, Le Maignan C, Marjanovic Z, Farge D. Frere C, et al. Among authors: le maignan c. J Clin Med. 2022 Jun 28;11(13):3729. doi: 10.3390/jcm11133729. J Clin Med. 2022. PMID: 35807014 Free PMC article.
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19.
Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Muñoz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-García LA, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. Farge D, et al. Lancet Oncol. 2022 Jul;23(7):e334-e347. doi: 10.1016/S1470-2045(22)00160-7. Lancet Oncol. 2022. PMID: 35772465 Free PMC article. Review.
Patient education program at the forefront of cancer-associated thrombosis care.
Sebuhyan M, Crichi B, Deville L, Le Maignan C, Bonnet C, Marjanovic Z, Rueda J, Bensaoula O, Ndour A, Frere C, Madeleine I, Farge D. Sebuhyan M, et al. Among authors: le maignan c. J Med Vasc. 2021 Oct-Dec;46(5-6):215-223. doi: 10.1016/j.jdmv.2021.08.001. Epub 2021 Aug 24. J Med Vasc. 2021. PMID: 34862015
Treatment of 120 adult osteosarcoma patients with metachronous and synchronous metastases: A retrospective series of the French Sarcoma Group.
Lavit E, Aldea M, Piperno-Neumann S, Firmin N, Italiano A, Isambert N, Kurtz JE, Delcambre C, Lebrun V, Soibinet-Oudot P, Chevreau C, Bompas E, Le Maignan C, Boudou-Rouquette P, Le Cesne A, Mancini J, Blay JY, Duffaud F. Lavit E, et al. Among authors: le maignan c. Int J Cancer. 2022 Feb 15;150(4):645-653. doi: 10.1002/ijc.33823. Epub 2021 Oct 5. Int J Cancer. 2022. PMID: 34562271
Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study.
Benzidia I, Crichi B, Montlahuc C, Rafii H, N'Dour A, Sebuhyan M, Gauthier H, Ait Abdallah N, Benillouche P, Villiers S, Le Maignan C, Farge D. Benzidia I, et al. Among authors: le maignan c. J Thromb Thrombolysis. 2022 Feb;53(2):417-424. doi: 10.1007/s11239-021-02512-5. Epub 2021 Jul 22. J Thromb Thrombolysis. 2022. PMID: 34296382
Long-Term Outcome of Neoadjuvant Tyrosine Kinase Inhibitors Followed by Complete Surgery in Locally Advanced Dermatofibrosarcoma Protuberans.
Beaziz J, Battistella M, Delyon J, Farges C, Marco O, Pages C, Le Maignan C, Da Meda L, Basset-Seguin N, Resche-Rigon M, Walter Petrich A, Kérob D, Lebbé C, Baroudjian B. Beaziz J, et al. Among authors: le maignan c. Cancers (Basel). 2021 May 6;13(9):2224. doi: 10.3390/cancers13092224. Cancers (Basel). 2021. PMID: 34066400 Free PMC article.
Women, thrombosis, and cancer.
Farge D, Le Maignan C, Doucet L, Frere C. Farge D, et al. Among authors: le maignan c. Thromb Res. 2019 Sep;181 Suppl 1:S47-S53. doi: 10.1016/S0049-3848(19)30367-6. Thromb Res. 2019. PMID: 31477228 Review.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
53 results